Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pozen has reported the long-term safety results of open-label study 303 of PA32540 which is used for the secondary prevention of cardiovascular disease in patients at risk for developing aspirin-associated gastric ulcers.
Subscribe to our email newsletter
PA32540 is an investigational coordinated-delivery tablet of immediate-release omeprazole, a proton pump inhibitor (PPI), layered around pH-sensitive aspirin.
During the trial, subjects with known cardiovascular disease and already taking aspirin at a dose of 325 mg once daily, were treated with PA32540 instead of their usual aspirin product once daily for as long as one year.
The trial results demonstrated that of the 379 patients enrolled in this trial, 290 completed therapy for one year, 51 withdrew from the trial because of any adverse event, and one patient died.
Pozen Development executive vice president Tomas Bocanegra said these data support the possibility that long-term treatment with PA32540 may provide patients with a safe and effective option for secondary prevention of cardiovascular events, including heart attacks and strokes.
"As soon as we obtain the results of the two ongoing pivotal Phase 3 trials in the first half of 2012, we will have all of the necessary components for the PA32540 NDA which is scheduled for submission to the FDA during the second half of 2012," Bocanegra said.